비즈니스 · 2011. 10. 12.1 분 읽기
Prospective Grant of Exclusive License: The Development of Human Anti-Mesothelin Monoclonal Antibodies for the Treatment of Human Cancers
로컬 자동 번역 · 원본 출처 언어
요약
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application 61/040,005 entitled "Human Monoclonal Antibodies Specific for Mesothelin" [HHS Ref. E-079-2008/0-US-01], PCT Application PCT/US2009/038228 entitled "Human Monoclonal Antibody Against Mesothelin" [HHS Ref. E-079-2008/0-PCT-02], Australian patent application AU 2009228361 entitled "Human Monoclonal Antibody Against Mesothelin" [HHS Ref. E-079-2008/0-AU-03], Canadian patent application CA 2718321 entitled "Human Anti-Mesothelin Monoclonal Antibodies" [HHS Ref. E-079-2008/0-CA-04], European patent application EP 09726082.2 entitled "Human Monoclonal Antibody Against Mesothelin" [HHS Ref. E-079-2008/0-EP-05], U.S. patent application 12/934,060 entitled "Human Anti-Mesothelin Monoclonal Antibodies " [HHS Ref. E- 079-2008/0-US-06], and all related continuing and foreign patents/ patent applications for the technology family, to Sanomab, Ltd. The patent rights in these inventions have been assigned to and/